This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
XELJANZ® (tofacitinib citrate) Prescribing Information and Maxtrex (methotrexate) Prescribing Information. Adverse event reporting can be found at the bottom of the page.
Tofacitinib should only be used if no suitable treatment alternatives are available in patients:
These risks are considered class effects and relevant across all approved indications of JAKi in inflammatory and dermatologic diseases.
Biography
Professor Ramanan is a medical advisor for Olivia’s Vision. He is also Co-Chair for the National Institute for Health Research Clinical Research Network: Children/Arthritis Research UK (ARUK) Paediatric Rheumatology Clinical Studies Group. He was awarded the British Society of Rheumatology’s Innovation in Clinical Practice Award in 2010. He was also awarded the University of Bristol Vice Chancellor’s Health Impact award in 2017 and Royal College of Physicians/NIHR CRN Award for outstanding contribution to research in 2018.
Professor Ramanan’s has published >225 articles and numerous book chapters covering a variety of topics in the field of rheumatology. He is the Co-Editor of Rheumatology and Associate Editor for the Archives of Diseases in Childhood.
He is one of the Editors of 5th Edition of Oxford Textbook of Rheumatology.
He has also led pivotal trials of Tocilizumab and Baricitinib in COVID-19 and part of the paediatric steering committee of the RECOVERY trial.
Maxtrex (methotrexate) is not approved for use in JIA.
Set up a PfizerPro account to access further materials and resources, and receive communication about medicines and vaccines promoted by Pfizer.
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
Athimalaipet V. Ramanan is a consultant pediatric rheumatologist at the Bristol Royal Hospital for Children. He is the joint lead for research (Division of Women and Children) at the Bristol Royal Hospital for Children, and Professor of Paediatric Rheumatology at the University of Bristol.
In this video, watch Professor Ramanan share his views on the topic of XELJANZ in JIA.
Take a look at the Xeljanz JiA-1 clinical studies by clicking below.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024